✦ LIBER ✦

Concurrent Hyperfractionated Radiation Therapy and Chemotherapy in Locally Advanced (Stage III) Non-Small-Cell Lung Cancer: Single Institution Experience With 600 Patients

✍ Scribed by Branislav Jeremić; Biljana Miličić; Slobodan Milisavljevic

Book ID: 118455641
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 191 KB
Volume: 82
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2011.04.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity of concurrent hyperfractionated

Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients

✍ Branislav Jeremić, Biljana Miličić, Slobodan Milisavljevic 📂 Article 📅 2012 🏛 Springer Milan 🌐 Spanish ⚖ 180 KB

Clinical prognostic factors in patients

Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy : Single-Institution Experience in 600 Patients

✍ Branislav Jeremić; Biljana Miličić; Slobodan Milisavljevic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 2 views

Hyperfractionated radiation therapy with

Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non–small cell lung cancer

✍ Branislav Jeremic; Stanisa Jevremovic; Ljiljana Mijatovic; Slobodan Milisavljevi 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB 👁 2 views

From conventionally fractionated radiati

From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer

✍ Branislav Jeremić; Biljana Miličić 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract ## BACKGROUND The authors' single‐institution experience in patients with early‐stage (I and II) nonsmall cell lung cancer (NSCLC) who were treated between 1980 and 1998 with either conventionally fractionated (CF) radiation therapy (RT), or hyperfractionated (HFX) RT, or HFX RT with c

Hyperfractionated radiation therapy and

Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial

✍ B Jeremic; Y Shibamoto; L Acimovic; B Milicic; S Milisavljevic; N Nikolic; A Dag 📂 Article 📅 2002 🏛 Elsevier Science 🌐 French ⚖ 18 KB

788 Pretreatment clinical prognostic fac

788 Pretreatment clinical prognostic factors influencing survival in patients with stage III non-small cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy (HFX RT) with or without concurrent chemotherapy (CHT)

✍ B. Jeremic; B. Millicic; A. Dagovic; S. Dagovic; J. Stankovic; J. Aleksandrovic; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 163 KB